WHO's clearance to Bharat Biotech's Covaxin delayed: Reports
New Delhi/IBNS: The World Health Organization (WHO) has further delayed the emergency use authorisation (EUA) for Covaxin, the COVID vaccine developed in India by pharmaceutical company Bharat Biotech, media reports said.
This delay will be a major setback for all those aspiring for international travels, especially students who want to go abroad.
Without an EUA, Covaxin will not be considered an accepted vaccine by most countries to allow entry to such vaccinated students.
WHO's delay for Bharat Biotech comes despite the Hyderabad-based drug maker asserting that it has submitted all data required for a clearance.
The Union Health Ministry earlier hinted that the global body was likely to give its nod anytime soon.
Serum Institute's Covishield is the only Indian-made vaccine to find a place in the list of approved ones globally for now.
India is also among the 33 countries from where fully vaccinated travellers will be allowed to enter the United States from November.
So far, only seven vaccines have been approved for use by the WHO including Moderna, Pfizer-BioNTech, Johnson & Johnson, Oxford-AstraZeneca, Covishield (an Oxford-AstraZeneca formulation) and China's Sinopharm and Sinovac.